BioTime, Inc (BTX) - NYSEMKT
  • Tue, May 10, 5:24 PM
    • BioTime (NYSEMKT:BTX): Q1 EPS of -$0.19 misses by $0.05.
    • Revenue of $2.07M (+64.3% Y/Y) beats by $0.64M.
    • Press Release
    | Tue, May 10, 5:24 PM
  • Nov. 9, 2015, 8:16 AM
    • BioTime (NYSEMKT:BTX): Q3 EPS of -$0.18
    • Revenue of $2.31M (+94.1% Y/Y)
    | Nov. 9, 2015, 8:16 AM
  • Aug. 10, 2015, 5:22 PM
    • BioTime (NYSEMKT:BTX): Q2 EPS of -$0.12
    • Revenue of $2.01M (+82.7% Y/Y)
    | Aug. 10, 2015, 5:22 PM
  • May 11, 2015, 10:35 AM
    • BioTime (BTX -0.2%) Q1 results: Revenues: $1.3M (+18.2%); COGS: $0.3M (+200.0%); R&D Expense: $9.3M (+10.7%); SG&A: $5.2M (+40.5%); Operating Loss: ($13.5M) (-21.6%); Net Loss: ($12.6M) (-29.9%); Loss Per Share: ($0.13) (+7.1%); Quick Assets: $25.8M (-12.5%).
    • No guidance given.
    | May 11, 2015, 10:35 AM
  • May 11, 2015, 8:22 AM
    • BioTime (NYSEMKT:BTX): Q1 EPS of -$0.13
    • Revenue of $1.26M (+17.8% Y/Y)
    | May 11, 2015, 8:22 AM | 1 Comment
  • Mar. 11, 2015, 9:21 AM
    • BioTime (BTX -1.1%) Q4 results: Revenues: $1.9M (-0.3%); COGS: $0.3M (+0.2%); R&D Expense: $11.3M (+22.8%); SG&A: $4.8M (+11.6%); Operating Loss: ($14.4M) (+50.9%); Net Loss: ($10.6M) (+45.9%); Loss Per Share: ($0.14) (+60.0%).
    • FY2014 results: Revenues: $5.2M (+18.2%); COGS: $0.8M (+5.6%); R&D Expense: $37.5M (+41.0%); SG&A: $17.6M (+12.8%); Operating Loss: ($50.7M) (+9.5%); Net Loss: ($36.5M) (+16.9%); Loss Per Share: ($0.55) (+32.1%); Quick Assets: $29.5M (+436.4%).
    • No guidance given.
    | Mar. 11, 2015, 9:21 AM | 3 Comments
  • Mar. 11, 2015, 8:11 AM
    • BioTime (NYSEMKT:BTX): Q4 EPS of -$0.14
    • Revenue of $1.9M (flat Y/Y)
    | Mar. 11, 2015, 8:11 AM
  • Nov. 10, 2014, 9:08 AM
    • BioTime (NYSEMKT:BTX): Q3 EPS of -$0.12.
    • Revenue of $1.2M (+71.4% Y/Y).
    | Nov. 10, 2014, 9:08 AM
  • Aug. 12, 2014, 10:04 AM
    • BioTime (BTX -2.8%) Q2 results: Revenues: $1.1M (-9.0%); Operating Loss: ($13.1M) (-60.9%); Net Loss: ($11.4M) (-39.0%); Loss Per Share: ($0.16) (-14.3%); Quick Assets: $15.7M (+185.5%).
    • No financial guidance given.
    | Aug. 12, 2014, 10:04 AM
  • Aug. 12, 2014, 8:15 AM
    • BioTime (NYSEMKT:BTX): Q2 EPS of -$0.16
    • Revenue of $1.1M (-9.1% Y/Y)
    | Aug. 12, 2014, 8:15 AM
  • May 12, 2014, 9:22 AM
    • BioTime (BTX): Q1 EPS of -$0.14.
    • Revenue of $1.1M (+83.3% Y/Y).
    | May 12, 2014, 9:22 AM
  • Mar. 18, 2014, 5:43 AM
    • BioTime (BTX): Q4 EPS of -$0.35
    • Revenue of $1.9M (+58.3% Y/Y)
    | Mar. 18, 2014, 5:43 AM
  • Nov. 12, 2013, 5:40 PM
    • BioTime (BTX): FQ3 EPS of -$0.16 vs. -$0.10 last year.(PR)
    | Nov. 12, 2013, 5:40 PM
  • Mar. 19, 2013, 12:51 PM

    BioTime (BTX -7.6%) takes a hit today after reporting late Monday a Q4 loss of $0.12 per share, compared with a loss of $0.11 per share in the same period last year. Revenues were $1.22M, also down from the prior-year quarter. Total revenue decreased by 9% Y/Y, primarily due to lower grant revenue stemming from the completion of it's research grant from the California Institute for Regenerative Medicine, and an overall decrease in the sale of research products.

    | Mar. 19, 2013, 12:51 PM
  • Mar. 19, 2013, 6:48 AM
    BioTime (BTX): Q4 EPS of -$0.12. Revenue of $1.2M (-30% Y/Y). (PR)
    | Mar. 19, 2013, 6:48 AM
Company Description
BioTime, Inc. is a biotechnology company, which is focused on regenerative medicine and blood plasma volume expanders. The company provides research and product development in the field of regenerative medicine. It develops blood plasma volume expanders, blood replacement solutions for... More
Sector: Healthcare
Industry: Biotechnology
Country: United States